Triple-Negative Breast Cancer: The RI-MUHC Enrolls First Patients in International Phase III Clinical Trial

The Research Institute of the McGill University Health Centre (RI-MUHC) announced the initiation of a new randomized Phase III clinical trial, TROPION-Breast03, to test the efficacy of datopotamab deruxtecan with or without durvalumab as an adjuvant therapy for patients with Stage I-III TNBC.